JP2016506388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506388A5 JP2016506388A5 JP2015545868A JP2015545868A JP2016506388A5 JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5 JP 2015545868 A JP2015545868 A JP 2015545868A JP 2015545868 A JP2015545868 A JP 2015545868A JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- nos
- sequence consisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 78
- -1 lenalidomide compound Chemical class 0.000 claims 29
- 229960004942 lenalidomide Drugs 0.000 claims 24
- 229960003957 dexamethasone Drugs 0.000 claims 18
- 239000003146 anticoagulant agent Substances 0.000 claims 12
- 229940127219 anticoagulant drug Drugs 0.000 claims 12
- 208000034578 Multiple myelomas Diseases 0.000 claims 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 10
- 239000002955 immunomodulating agent Substances 0.000 claims 10
- 229940121354 immunomodulator Drugs 0.000 claims 10
- 230000002584 immunomodulator Effects 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 10
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 9
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 5
- 229960003433 thalidomide Drugs 0.000 claims 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000003055 low molecular weight heparin Substances 0.000 claims 2
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 229960005080 warfarin Drugs 0.000 claims 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734524P | 2012-12-07 | 2012-12-07 | |
| US61/734,524 | 2012-12-07 | ||
| US201361769247P | 2013-02-26 | 2013-02-26 | |
| US61/769,247 | 2013-02-26 | ||
| US201361808372P | 2013-04-04 | 2013-04-04 | |
| US61/808,372 | 2013-04-04 | ||
| PCT/US2013/073540 WO2014089416A1 (en) | 2012-12-07 | 2013-12-06 | Compositions comprising anti-cd38 antibodies and lenalidomide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019003132A Division JP2019070020A (ja) | 2012-12-07 | 2019-01-11 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506388A JP2016506388A (ja) | 2016-03-03 |
| JP2016506388A5 true JP2016506388A5 (enExample) | 2017-01-19 |
| JP6499971B2 JP6499971B2 (ja) | 2019-04-10 |
Family
ID=50884019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545868A Active JP6499971B2 (ja) | 2012-12-07 | 2013-12-06 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
| JP2019003132A Pending JP2019070020A (ja) | 2012-12-07 | 2019-01-11 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019003132A Pending JP2019070020A (ja) | 2012-12-07 | 2019-01-11 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP3597191A1 (enExample) |
| JP (2) | JP6499971B2 (enExample) |
| KR (2) | KR20200143503A (enExample) |
| CN (1) | CN105263520B (enExample) |
| AR (1) | AR093844A1 (enExample) |
| AU (2) | AU2013355064B2 (enExample) |
| BR (1) | BR112015012987A2 (enExample) |
| CA (1) | CA2893946A1 (enExample) |
| CL (2) | CL2015001558A1 (enExample) |
| CY (2) | CY1122478T1 (enExample) |
| DK (1) | DK2928495T3 (enExample) |
| ES (1) | ES2731548T3 (enExample) |
| HR (1) | HRP20191034T1 (enExample) |
| HU (3) | HUE044142T2 (enExample) |
| IL (2) | IL239234B (enExample) |
| LT (2) | LT2928495T (enExample) |
| LU (1) | LUC00187I2 (enExample) |
| MX (2) | MX366296B (enExample) |
| MY (1) | MY191601A (enExample) |
| NL (1) | NL301079I2 (enExample) |
| NZ (1) | NZ709215A (enExample) |
| PH (1) | PH12015501263A1 (enExample) |
| PL (1) | PL2928495T3 (enExample) |
| PT (1) | PT2928495T (enExample) |
| RS (1) | RS58829B1 (enExample) |
| RU (1) | RU2698911C2 (enExample) |
| SG (3) | SG11201504315WA (enExample) |
| SI (1) | SI2928495T1 (enExample) |
| TW (2) | TWI670062B (enExample) |
| UA (1) | UA118255C2 (enExample) |
| WO (1) | WO2014089416A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015195555A1 (en) * | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| BR112019000544A2 (pt) | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| AU2019208102B2 (en) | 2018-01-12 | 2025-10-09 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| KR102286498B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드의 경구용 코팅 정제 조성물 |
| WO2019199135A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 |
| JP2021518424A (ja) * | 2018-04-13 | 2021-08-02 | サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ | 様々な用量のレナリドミドの経口用錠剤組成物 |
| KR102286500B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 |
| KR102286499B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드를 포함하는 약제학적 조성물 |
| AU2019270624B2 (en) | 2018-05-16 | 2024-05-02 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics |
| AU2019351811B2 (en) * | 2018-10-01 | 2025-01-02 | Celgene Corporation | Combination therapy for the treatment of cancer |
| WO2020187718A1 (en) * | 2019-03-15 | 2020-09-24 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| EP3980064A1 (en) * | 2019-06-10 | 2022-04-13 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| PH12022551008A1 (en) * | 2019-10-31 | 2023-03-20 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| CN115698064A (zh) | 2019-12-05 | 2023-02-03 | 赛诺菲-安万特美国有限责任公司 | 用于皮下施用的抗cd38抗体的配制品 |
| US20250277051A1 (en) * | 2021-08-02 | 2025-09-04 | Hangzhou Unogen Biotech, Ltd | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN101084252B (zh) * | 2004-12-21 | 2012-06-13 | 日本化药株式会社 | 环氧树脂、环氧树脂组合物及其固化物 |
| EA015584B1 (ru) * | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| HRP20191115T1 (hr) * | 2006-09-26 | 2019-09-20 | Genmab A/S | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
-
2013
- 2013-06-12 UA UAA201506686A patent/UA118255C2/uk unknown
- 2013-12-06 JP JP2015545868A patent/JP6499971B2/ja active Active
- 2013-12-06 LT LTEP13861470.6T patent/LT2928495T/lt unknown
- 2013-12-06 MX MX2015007189A patent/MX366296B/es active IP Right Grant
- 2013-12-06 DK DK13861470.6T patent/DK2928495T3/da active
- 2013-12-06 CA CA2893946A patent/CA2893946A1/en not_active Abandoned
- 2013-12-06 BR BR112015012987A patent/BR112015012987A2/pt not_active Application Discontinuation
- 2013-12-06 RS RS20190711A patent/RS58829B1/sr unknown
- 2013-12-06 TW TW102145031A patent/TWI670062B/zh active
- 2013-12-06 TW TW107134543A patent/TW201919699A/zh unknown
- 2013-12-06 PT PT13861470T patent/PT2928495T/pt unknown
- 2013-12-06 ES ES13861470T patent/ES2731548T3/es active Active
- 2013-12-06 SG SG11201504315WA patent/SG11201504315WA/en unknown
- 2013-12-06 MY MYPI2015701779A patent/MY191601A/en unknown
- 2013-12-06 KR KR1020207035944A patent/KR20200143503A/ko not_active Ceased
- 2013-12-06 AU AU2013355064A patent/AU2013355064B2/en active Active
- 2013-12-06 SI SI201331472T patent/SI2928495T1/sl unknown
- 2013-12-06 KR KR1020157017942A patent/KR102193045B1/ko active Active
- 2013-12-06 WO PCT/US2013/073540 patent/WO2014089416A1/en not_active Ceased
- 2013-12-06 AR ARP130104546A patent/AR093844A1/es unknown
- 2013-12-06 SG SG10201913783PA patent/SG10201913783PA/en unknown
- 2013-12-06 EP EP19164801.3A patent/EP3597191A1/en not_active Withdrawn
- 2013-12-06 HR HRP20191034TT patent/HRP20191034T1/hr unknown
- 2013-12-06 SG SG10201704536PA patent/SG10201704536PA/en unknown
- 2013-12-06 CN CN201380063714.0A patent/CN105263520B/zh active Active
- 2013-12-06 PL PL13861470T patent/PL2928495T3/pl unknown
- 2013-12-06 HU HUE13861470A patent/HUE044142T2/hu unknown
- 2013-12-06 RU RU2015127089A patent/RU2698911C2/ru active
- 2013-12-06 NZ NZ709215A patent/NZ709215A/en unknown
- 2013-12-06 EP EP13861470.6A patent/EP2928495B1/en active Active
-
2015
- 2015-06-03 PH PH12015501263A patent/PH12015501263A1/en unknown
- 2015-06-04 IL IL239234A patent/IL239234B/en active IP Right Grant
- 2015-06-05 CL CL2015001558A patent/CL2015001558A1/es unknown
- 2015-06-05 MX MX2019008065A patent/MX2019008065A/es unknown
-
2018
- 2018-08-01 AU AU2018211258A patent/AU2018211258A1/en not_active Abandoned
- 2018-11-20 CL CL2018003292A patent/CL2018003292A1/es unknown
-
2019
- 2019-01-11 JP JP2019003132A patent/JP2019070020A/ja active Pending
- 2019-06-26 CY CY20191100667T patent/CY1122478T1/el unknown
-
2020
- 2020-11-25 LU LU00187C patent/LUC00187I2/fr unknown
- 2020-11-27 CY CY2020040C patent/CY2020040I2/el unknown
- 2020-11-30 NL NL301079C patent/NL301079I2/nl unknown
- 2020-11-30 LT LTPA2020537C patent/LTC2928495I2/lt unknown
- 2020-11-30 HU HUS2000051C patent/HUS2000051I1/hu unknown
- 2020-11-30 HU HUS2000050C patent/HUS2000050I1/hu unknown
-
2021
- 2021-04-21 IL IL282542A patent/IL282542A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506388A5 (enExample) | ||
| JP2016514148A5 (enExample) | ||
| RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
| JP2016536314A5 (enExample) | ||
| JP2014076062A5 (enExample) | ||
| JP2017048208A5 (enExample) | ||
| RU2015143462A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2013537418A5 (enExample) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2018534933A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| JP2010500370A5 (enExample) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2015532292A5 (enExample) | ||
| JP2019531764A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| JP2017507954A5 (enExample) | ||
| JP2010500371A5 (enExample) | ||
| JP2017515815A5 (enExample) | ||
| JP2012523417A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2018520101A5 (enExample) |